MARKET

CEMI

CEMI

Chembio Diagnostics Inc
NASDAQ
0.4370
+0.0214
+5.15%
After Hours: 0.4400 +0.003 +0.69% 18:47 10/06 EDT
OPEN
0.4200
PREV CLOSE
0.4156
HIGH
0.4400
LOW
0.3800
VOLUME
918.50K
TURNOVER
0
52 WEEK HIGH
2.550
52 WEEK LOW
0.3250
MARKET CAP
13.21M
P/E (TTM)
-0.3569
1D
5D
1M
3M
1Y
5Y
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Yesterday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Benzinga · 3d ago
'Ohio reports state's first death from monkeypox, raising U.S. death toll to 3' -BNO Report
https://twitter.com/BNOFeed/status/1575847127166713860
Benzinga · 6d ago
U.S. CDC Director Walensky Says U.S. Moving To Pre-exposure Prophylaxis Strategy For Monkeypox Vaccine
- Reuters 
Benzinga · 09/28 15:58
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Benzinga · 09/27 18:14
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and
Benzinga · 09/23 12:02
European Union Drug Regulator European Medicines Agency Says Monkeypox Infection Trend Gives Hope That The Outbreak Can Be Contained
- Reuters 
Benzinga · 09/20 13:45
Earlier Announced: China Records First Monkeypox Case
The infected patient, who had arrived in Chongqing from overseas, developed symptoms while in Covid quarantine China has been on high alert for the disease since it started spreading rapidly in Europe and the Americas
Benzinga · 09/16 14:51
U.S. CDC Director Says U.S. Monkeypox Cases Are About 23000 As Of Sept 14, There Is Decline In Growth Of New Cases; There Are Some Areas In U.S. Still Seeing Rise In Monkeypox Cases
- Reuters  
Benzinga · 09/15 14:52
More
About CEMI
Chembio Diagnostics, Inc. develops and commercializes point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19, and other viral and bacterial infections, enabling expedited treatment. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. It is also targeting lateral flow test solutions for infectious diseases.

Webull offers kinds of Chembio Diagnostics Inc stock information, including NASDAQ:CEMI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CEMI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CEMI stock methods without spending real money on the virtual paper trading platform.